Been there done that.
Back in the day before MiniMed was acquired by Medtronic an executive said running an insulin pump company is like running an airline, you never shut down. Insulin pumps have become much smarter since then, there are new forms of information readily available to patients, yet this is a medical device and as much patients don’t like it medical devices fail and/or malfunction. Perhaps the biggest strategic blunder made by Medtronic...
No drama here
With each passing earnings call it’s getting more difficult to say the same thing in a different way. And quite frankly it doesn’t matter whose earnings are being released Abbott or in this case Dexcom. The CGM market is their domain, they own it, will continue to own it and barring a major screw up will own it for quite some time. Their systems are only getting better, access to...
Hypocrisy in its highest form.
Roughly two out of three U.S. adults are overweight or obese (69 percent) and one out of three are obese (36 percent). – Harvard school of public health The US obesity prevalence was 41.9% in 2017 - CDC The estimated annual medical cost of obesity in the United States was nearly $173 billion in 2019 dollars. Medical costs for adults who had obesity were $1,861 higher than medical costs for people with...
Off we GO
This morning Insulet announced they had received FDA approval for the basal only system the Omnipod GO. Now we’ll state upfront that we don’t expect the GO to add materially to Insulet’s bottom line. This is really nothing against the GO it’s just we don’t believe in basal only systems such as the GO. Yet unlike other basal only systems the GO has some things going for it that the...
Two different fights
The big news in the diabetes toy world was the approval of the Medtronic 780G. The big news in the diabetes/obesity drug world was Lilly’s new study which will pit Mounjaro against Wegovy head-to-head. Each piece of news represents a fight, one for survival the other for supremacy. Let’s take the Medtronic news first. Medtronic CEO Geoff Martha has stated many times that the 780G will reverse the tide for Medtronic...
It’s not the when, it’s the how.
Yesterday after Abbott reported results this appeared in a post on the Fierce Biotech web site. “The strong performance in diabetes tech sales may go a long way in outweighing Abbott’s losses in COVID testing, according to Third Bridge senior analyst George Congdon, who wrote of the department’s earnings, “This news is particularly well received given the FDA’s 2023 clearance of the Freestyle Libre 2 and 3 sensors to integrate with...
New paths to success
Far too often in this wacky world of ours, people get overly excited about the hardware, yep everyone loves the toys in the toy chest. Yes, hardware is way cool and can be very whiz bang but in the end it’s also a commodity. While none of the hardware companies like to acknowledge this all the toys do basically the same thing the same way. The Control IQ, Omnipod 5 and...